Injectable Contraceptive Study

The purpose of this study is to investigate levonorgestrel butanoate (LB) as a possible long-acting and reversible injectable for contraception. 

This study is being done in order to investigate levonorgestrel butanoate (LB) as a possible long-acting and reversible injectable for contraception. Injectable contraception is a long-acting and reversible method of birth control. An experimental injectable contraceptive containing levonorgestrel butanoate (also called LB) has been developed by the NICHD. An experimental use is one that is not approved by the United States Food and Drug Administration (FDA).

WHRU - Injection Contraceptive Study

LB is a type of hormone called a progestin. The hormone is intended to keep or delay women from releasing an egg, so they do not get pregnant and also may work by thickening the cervical mucus to prevent the passage of sperm and by preventing sperm from fertilizing an egg. Approved levonorgestrel birth control pills work the same way.  It is not known how well the new LB injection will work in preventing a woman from becoming pregnant. This study is intended to help find out what effects the hormones will have on women who receive the injection.

Eligibility:

You might be eligible for this study if:

  • You are between the ages of 18 and 40
  • You have regular menstrual cycles every 21-35 days
  • You are in good general health
  • You use non-hormonal contraception, like condoms, copper IUD, tubal ligation or vasectomy or are willing to not have sex with men during the study

Compensation:

Qualified participants may be compensated up to $1760 for time and travel.

Whom do I contact for additional information?

To find out more information and to learn if you are qualified to participate, fill out the online form or call the Women’s Health Research Unit confidential recruitment line at 503-494-3666 or email us at whru@ohsu.edu.